# Anaeropharma Science

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/anaeropharma-science

- Industry: Biotechnology
- Headquarters: Tokyo, Japan
- Total disclosed funding: $12M
- Latest round: Series H (Jul 5, 2017)
- Investors on record: 5

## About

Founded in 2004 and based in Tokyo, Japan, Anaeropharma Science, Inc. operates as a biopharmaceutical company that develops therapeutics to target such a hypoxic environment in solid cancers based on its proprietary platform technology. In November 2022, Anaeropharma Science, Inc. raised an undisclosed amount of venture funding from returning investor Seventure.

Anaeropharma’s offers a proprietary platform, i-DPS (intelligent Drug Delivery System), that enables localized drug activation.  Its lead technology, i-DPS, utilizes recombinant Bifidobacterium to selectively colonize hypoxic tumor regions. Once localized, the bacteria express enzymes that convert systemically administered prodrugs into active cytotoxic agents directly within the tumor microenvironment. This approach minimizes systemic toxicity and enhances therapeutic precision. The platform has potential applications in oncology and other diseases characterized by hypoxia.

## Funding rounds

- Series H, Jul 5, 2017, $12M — Seventure Partners, INCJ, Mitsubishi UFJ Capital, Novartis, SBI Shinsei Corporate Investment

## Investors

- Seventure Partners (https://capitalatlas.ai/funds/seventure-partners) — Series H
- INCJ — Series H
- Mitsubishi UFJ Capital (https://capitalatlas.ai/funds/mitsubishi-ufj-capital) — Series H
- Novartis — Series H
- SBI Shinsei Corporate Investment (https://capitalatlas.ai/funds/sbi-shinsei-corporate-investment) — Series H